Evaluation of the efficacy, safety, and pharmacokinetics of nanodispersible cannabidiol oral solution (150mg/ml) versus placebo in mild to moderate anxiety subjects: A double blind multicenter randomized clinical trial

Anxiety disorders, an increasingly prevalent global mental health illness, affected approximately 301 million individuals worldwide in 2019. There is an unmet need for the treatment of anxiety disorders, as current therapies are associated with limited response rates, residual symptoms, and adverse effects.